Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Buspirone for poor esophageal motility and dysphagia
2019-002182-35Phase 3Active
- Sponsor
- KU Leuven
- Start
- Aug 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of buspirone in esophageal dysmotility and dysphagia (2 arms), sponsored by KU Leuven. Primary endpoint: Change in distal contractile integral for liquid bolus. Started Aug 2019; status: active.
02
Drugs
buspirone
03
Conditions
esophageal dysmotilitydysphagia
Beyond the preview
Go deeper on 2019-002182-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-002182-35.